Small vessel disease to subcortical dementia: a dynamic model, which interfaces aging, cholinergic dysregulation and the neurovascular unit

Paola Caruso
Riccardo Signori
Rita Moretti
Department of Medical, Surgical and Health Sciences, Neurology Clinic, University of Trieste, Trieste, Italy

Background: Small vessels have the pivotal role for the brain’s autoregulation. The arteriosclerosis-dependent alteration of the brain perfusion is one of the major determinants in small vessel disease. Endothelium distress can potentiate the flow dysregulation and lead to subcortical vascular dementia (sVAD). sVAD increases morbidity and disability. Epidemiological studies have shown that sVAD shares with cerebrovascular disease most of the common risk factors. The molecular basis of this pathology remains controversial.

Purpose: To detect the possible mechanisms between small vessel disease and sVAD, giving a broad vision on the topic, including pathological aspects, clinical and laboratory findings, metabolic process and cholinergic dysfunction.

Methods: We searched MEDLINE using different search terms ("vascular dementia", "subcortical vascular dementia", “small vessel disease”, “cholinergic afferents”, etc). Publications were selected from the past 20 years. Searches were extended to Embase, Cochrane Library, and LILIACS databases. All searches were done from January 1, 1998 up to January 31, 2018.

Results: A total of 560 studies showed up, and appropriate studies were included. Associations between traditional vascular risk factors have been isolated. We remarked that SVD and white matter abnormalities are seen frequently with aging and also that vascular and endothelium changes are related with age; the changes can be accelerated by different vascular risk factors. Vascular function changes can be heavily influenced by genetic and epigenetic factors.

Conclusion: Small vessel disease and the related dementia are two pathologies that deserve attention for their relevance and impact in clinical practice. Hypertension might be a historical problem for SVD and SVAD, but low pressure might be even more dangerous; CBF regional selective decrease seems to be a critical factor for small vessel disease-related dementia. In those patients, endothelium damage is a super-imposed condition. Several issues are still debatable, and more research is needed.

Keywords: subcortical vascular dementia, vascular damage, small vessel disease, brain’s autoregulation

Introduction: traditional perspectives and recently acquired information

Many authors have widely questioned vascular damage for its role in causing dementia. Consensus criteria for the clinical diagnosis of the significant dementing disorders have recently been updated, both for Alzheimer Disease (AD), Parkinson disease dementia (PDD) and Lewy Body Disease (DBL), Frontotemporal Lobe
Degeneration (FTLD).

Previous diagnostic criteria for vascular dementia (VaD) required the presence of memory loss and the severity of cognitive impairment sufficient to adversely affect independent functioning consistent with dementia. Despite multiple attempts, no generally accepted morphologic substrates have been included in the currently used clinical diagnostic criteria for VaD.

With time, different diagnostic guidelines for VaD have been described. The commonly used are the National Institute of Neurological Disorders and Stroke Association International pour la Recherche et l’Enseignement en Neurosciences (NINDS-AIREN) guideline. For completion of probable vascular dementia, all should be present:

1. Dementia as impairment of memory and any other 2 or more cognitive domains, preferably established by clinical examination and documented by the neuropsychological test.
2. The presence of cerebrovascular diseases as the presence of focal neurological signs and evidence of the same in the brain imaging.
3. A relationship between dementia and cerebrovascular disease as one or both:
   a. The onset of dementia within three months following a recognized stroke;
   b. Abrupt deterioration on cognitive functions or fluctuation, stepwise progression of cognitive deficits.

For subcortical ischemic vascular dementia, the brain imaging would show either the Binswanger-type white matter lesions or lacunar infarcts with the absence of cortical non-lacunar territorial infarct and watershed infarcts, and other causes of white matter lesions. The temporal relationship may also be absent.

The International Classification of disease, 10th revision (ICD-10) includes diagnostic features:

1. General criteria for dementia must be met;
2. Unequal distribution of deficits in higher cognitive functions, with some affected and others, relatively spared;
3. Focal brain damage as at least one of the following (Unilateral spastic weakness of the limbs, unilaterally increased tendon reflexes, extensor plantar response, pseudobulbar palsy);
4. Evidence from the history, examination or test of significant cerebrovascular disease, etiologically related to dementia.

ICD-10 distinguished between:

- vascular dementia of acute onset: as it usually develops within one month, but within no longer than three months after a succession of strokes, rarely after a single broad stroke;
- multi-infarct dementia: which onset is usually gradual (within three to six months, following many minor ischemic episodes).
- Subcortical vascular dementia: with a history of hypertension and clinical examination, along with investigations showing vascular disease to be located in the deep white matter of the cerebral hemispheres, with preservation of the cerebral cortex.

A more complex pathological description (mainly discussed below) has been employed, extending the clinical diagnosis to strategic infarct, hypoxic-ischemic dementia, venous infarct dementia, and hemorrhagic dementia.

Recently, the Diagnostic and Statistical Manual of Mental disorders (5th Edition) redefined some aspects of clinical classification, and all the dementias are called Neurocognitive disorders. Here, the probable vascular neurocognitive disorder is described by:

1. Criteria met for the major or mild neurocognitive disorder.
2. Clinical features are consistent with a vascular etiology, as either the following:
   a. the onset of the cognitive deficits is temporally related to one or more vascular events;
   b. Evidence for a decline is prominent in elaborate attention (including processing speed) and frontal executive functions;
   c. Evidence of the presence of cerebrovascular disease from history, physical examination and neuroimaging, considering sufficient to account for neurocognitive deficits.

Possible vascular neurocognitive disorders should be diagnosed as:

1. Clinical criteria supported by neuroimaging evidence of significant parenchymal injury attributed to the cerebrovascular disease.
2. The neurocognitive syndrome is temporally related to one or more documented cerebrovascular events.
3. Both clinical and genetic evidence of cerebrovascular disease is present.
The most recent position summarizes the Standards for reporting Vascular changes on eNeuroimaging (STRIVE) for a recommended standard for research with MRI, but also with CT, completed a structured process to develop a common advisory about terms and definitions for features visible on MRI and minimum standards for image acquisition. Signs of small vessel disease include a conventional MRI recent subcortical infarcts, white matter hyperintensities, lacunes, prominent perivascular spaces, and cerebral microbleeds, with possible consequent atrophy.

Vascular cognitive alterations are described as due to vascular dementia (VaD). Other include vascular cognitive disorder (VCD), while subcortical VAD (sVAD) has been employed to define a circumscribed syndrome, related to small vessel disease. Being so difficult to categorize the different vascular subtypes of dementia, today it is widely accepted to define the cognitive impairment related to vascular dementia as Vascular Cognitive Impairment (VCI).

VCI refers to a vast and almost comprehensive spectrum of vascular brain pathologies that contribute to cognitive impairment, ranging from mild and subjective cognitive decline to overt dementia. The difference between VaD subtypes may depend on the anatomical distribution of the vascular insults. Usually, small artery disease is more often associated with subcortical VaD than with cortical and cortical-subcortical VaD. Subcortical VaD is homogeneous, with the small-vessel disease as the primary vascular etiology, lacunar infarcts, and ischemic white matter lesions.

Cerebral small vessel disease (SVD) is an umbrella term covering a variety of abnormalities related to small blood vessels in the brain. SVD results from damage to the small penetrating arteries and arterioles in the brain, the prevalence of SVD increases exponentially with aging: from approximately 6% to 7% at age 60 to 28% at age 80.

Cerebral small vessel disease (SVD) is a common cause of stroke, cognitive impairment, and gait disturbances, which slowly progress to vascular Parkinsonism and dementia but can be differentiated from Alzheimer’s disease considering neuroimaging findings (it is associated with more extensive white matter lesions, less severe hippocampal atrophy and the absence of cerebral amyloid angiopathy).

Substantial evidence shows that small vessel disease shares many risk factors and prognostic impacts in specific clinical settings. Moreover, inducing an increased blood pressure and hyperglycemia, the presence of small vessel disease confers a risk of hemorrhagic transformation in brain ischemia in 10% of cases.

In the clinical practice, small vessel disease is generally associated with the typical vascular “static” risk factors, such as hypertension, hyperlipidemia, diabetes, obesity, atherosclerosis, atrial fibrillation, and insufficient physical aerobic activity. Vascular Dementia increases the morbidity, disability, and healthcare costs of the growing elderly population, decreasing their quality of life. Its prevention and treatment are critical research and clinical priorities.

Neuropsychological pattern profiles of sVaD are distinguished by poor executive function, poor planning, working memory alterations, loss of inhibition, reduced mental flexibility, multitasking procedures invalidation, and decrease speed of executive process. Neuroimaging standards implement the clinical definition of subcortical vascular dementia, which relies on cerebral small vessel disease. Different studies have been realized with this aim.

Our works purposes were to detect the possible mechanisms between small vessel disease and sVaD, giving a broad vision on the topic, including pathological aspects, clinical and laboratory finding, metabolic processes and cholinergic dysfunction, pointing out the dynamic process that links small vessel disease to subcortical dementia, describing some crucial measures able to delay or even interrupt this process.

Search strategy and selection criteria
We searched MEDLINE using the search terms “vascular dementia,” “subcortical vascular dementia,” “vascular cognitive impairment,” “small vessel disease,” “cholinergic afferents,” “arteriolosclerosis” “cerebral flow regulation,” “neurovascular coupling,” “endothelium,” smooth muscle cells arteries”.

Publications were selected mostly form the past 20 years, but did not exclude frequently referenced and highly regarded older publications. Researchers have been extended to EMBASE, with the same strings, to COCHRANE LIBRARY, to LILACS. All searches were done from January 1st, 1998 up to January 31st, 2018.

We have considered papers published in English, French, German and Italian. Secondary searching was performed using the bibliography of the most relevant articles (following PRISMA statement, 2009). Congress abstracts and isolated case reports were not considered. We searched the reference lists of articles identified by this
Cerebral small vessel disease and blood pressure management

Collecting evidence suggests associations between traditional vascular risk factors, such as hypertension, diabetes, hypercholesterolemia, atherosclerosis, cardiovascular and cerebrovascular involvement, and cognitive disorders and dementia. These associations are complex and sometimes differ depending on when in life the risk factors are assessed.

Diabetes is a well-established risk factor for cognitive impairment, the mechanism of this process, however, is not fully understood. The effect of insulin acting directly on the brain is thought to increase the deposition and reduce the degradation of amyloid-β protein. Interestingly, Okereke et al showed that women without clinical diabetes but with higher levels of C-peptide, representing insulin secretion, had increased risk of cognitive impairment. Furthermore, Luchsinger et al showed that individuals with higher levels of fasting insulin, with or without clinical diabetes, exhibited a 70% higher risk of developing AD.

Hypertension has historically been considered as one of the most critical risk factors for vascular dementia development, as one of the many causative co-factor for neurodegenerative dementia, and for white matter lesions. Chronic hypertension has been shown to accelerate amyloid deposition, blood-brain barrier (BBB) dysfunction, microglial cells activation, and subsequent neuronal loss and cognitive impairment in animal models.

Rouch et al reported that patients showing a conversion from mild cognitive impairment to dementia were significantly older, more likely to have hypertension and cardiovascular diseases (Myocardial infarctions, including acute and subacute myocardial infarctions as well as older ischemic myocardial lesions). Moreover, long-standing hypertension is involved in the arterial aging process and arterial stiffness (also involved in the degenerative process).

Hypertension is a common risk factor for cerebral bleeding and hemorrhagic stroke, and it has been widely reported that there is a strict relationship between worse cognitive function and brain hemorrhage. For example, patients with Subarachnoid hemorrhage, who have no grossly evident neurological deficits after bleeding, frequently have subtle
cognitive or neurobehavioral difficulties that impair their social adjustment and ability to return to their previous occupations.

On the other side, several epidemiological studies have also described low blood pressure, especially in later life as a risk factor for the development of AD, pointing to the potential risk of over treating hypertension. Indeed, the impact of hypertension on VAD has been debated and explained by several mechanisms, centering white matter damages. It has also been found that hypertension is equally distributed in non-lacunar and lacunar lesions and that many patients with lacunar stroke are normotensive. Thus it remains to clarify whether hypertension alone affects cognitive function or if it is the effect of higher blood pressure on the cardiovascular system that is the cause.

The Bronx Aging Study, followed an elderly non-demented cohort (75 years old), for up to 21 years. Dementia was diagnosed following detailed neuropsychological testing, clinical examination, and neuroimaging. Over a median follow-up of 6.7 years, 122 subjects developed dementia, of these 65 had AD. Participants with diastolic blood pressure (DBP) of <70 mmHg were twice as likely to develop AD when compared to those with a DBP >90 mmHg. The risk was higher in individuals with a persistently low diastolic blood pressure.

Low blood pressure was described as a predictor of increased mortality in a 5-year prospective study in Finland Zhu et al. found a significant correlation between low systolic blood pressure and dementia and hypothesized that hypotension could be interpreted as a precocious sign of cognitive decline. This finding was confirmed by Ruitenberg et al. who found that low blood pressure is related to a higher risk of developing dementia, regardless of sex or dementia-type (both AD and vascular). The risk was more evident in subjects who were permitted to continue antihypertensive drugs, suggesting that these patients become more prone to hemodynamic changes, with a higher incidence of watershed infarcts. Burke and colleagues firstly suggested that AD patients suffered due to pressure dysregulation, caused by cholineric impairment. Guo et al. reported an association between increased dementia incidence and a relatively low systolic pressure, associated to a reduction of cerebral flow (CBF). The reduced CBF might be related to changes in cerebral vascular autoregulation due to the superimposing vessel degeneration, the same analysis was also reported elsewhere.

Nilsson et al. reported that in subjects aged 80 or older, higher systolic blood pressure was associated with a better cognitive function and a lower systolic blood pressure was associated with cognitive decline and dementia. Also, many other studies reported a possible effect of low blood pressure on the cognitive decline. Guidelines published by the American Society of Hypertension and the International Society of Hypertension in 2014, suggest a blood pressure <140/90 mmHg for patients younger than 80 years old, the European Society has suggested a similar target for Hypertension (ESH) and by the European Society of Cardiology (ESC). The Guideline by the Eighth Joint National Committee (JNC8) endorses a reasonable target (<150/90 mmHg) in patients aged 80 years old.

It appears that white matter alterations are exacerbated by a significant decrease in blood pressure. The most recently published work certified that “midlife not late-life exposure to the vascular risk factors is important for the development of dementia”.

Vascular aging is associated with changes in the mechanical and structural properties of vessel walls, which leads to the loss of arterial elasticity reducing arterial compliance. This induces an alteration in autoregulatory capabilities of cerebral arteries, responsible of cerebral perfusion at a constant rate of blood pressure (BP). In this situation, the brain may be more vulnerable to ischemic insults when systemic blood pressure dips below a critical threshold for maintaining perfusion. Orthostatic hypotension is arbitrarily defined as a fall in systolic BP of 20 mmHg, or a fall in DBP of 10 mmHg on standing, but when associated with symptoms suggestive of cerebral hyperperfusion, an even smaller drop in BP may be of equal importance.

Several studies have shown an association between severe cognitive impairment and dysregulation of postural blood pressure. Sudden postural hypotension can cause relatively prolonged changes in brain perfusion and may contribute to cause small lacunar events or contribute to white matter alterations and leukoaraiosis. Two recent studies found that orthostatic hypotension was more frequent in AD, with white matter disease than in AD without white matter disease. It has been speculated that a lack of capacity to regulate abnormal blood pressure, well recognized in AD, leads to chronic dysfunction of cerebral perfusion and leaves room for the development of white matter disease.

Bytheway, in the end, some studies imply that there is a connection between cognitive impairment and hypertension, whereas others claim the opposite.
Considering other risk factors for dementia, the recent SPRINT-MIND study showed that higher urine albumin concentration was independently associated with worse cognitive functioning, including global cognitive function, executive function, and attention; lower estimated glomerular filtration rate was independently associated with worse global function and memory, assessing that there is a strict association between chronic kidney disease and poorer cognitive function. In the same paper is remarked that the conversion of patients with mild cognitive impairment to AD is lower in those with well-controlled and lower blood pressure.99

**Pathological aspects of vascular cognitive impairment: the most updated vision**

A review of pathologic studies shows enormous differences in the prevalence of VaD ranging from 0.03 to 85.2% with means around 11%, while in recent autopsy series from Japanese geriatric hospitals it was 23.6 to 35%. Around Europe, prevalence rates of VaD between ages 65–69 to 80+ years ranged from 2.2 to 16.3%.10

Fisher was the pioneer in describing the neuropathological details in small vessel disease. From autopsy studies, he observed that majority of the lacunes were due to segmental arterial disorganization with asymmetrical focal vascular changes leading at the loss of standard architecture of the vessels, all these lesions particularly favor the development of spontaneous hemorrhage, especially in the deeper areas of the brain.100

The vessel disorders that are most frequently associated with VaD are atherosclerosis of cerebral arteries (AS), arteriosclerosis or cerebral small vessel disease (SVD), and cerebral amyloid angiopathy (CAA).101–104 These vessel disorders frequently occur in the brains of elderly individuals and become more prevalent and severe with advancing age. There are less common forms of cerebrovascular disease and cognitive impairment, including various types of vasculitis and inherited diseases that affect vessel integrity.

SVD can result in lacunar infarcts, microinfarcts, hemorrhages, and microbleeds.

In autopsy series of elderly subjects with and without dementia, the prevalence of “pure” VaD (without concomitant cerebral pathologies) ranged from 5 to 78%, in the oldest-old from 4.5 to 46.8%.105 The majority of patients showed Alzheimer-related pathology, only part of them with AD alone, while mixed pathologies, ie, AD plus cerebrovascular or Lewy pathology, were seen in 74–93% and 9–28%, respectively. In the age group 70 to 90+, the prevalence of VaD increased from 13 to 44.8%, compared to AD (23.6–57%) and mixed dementia (2–86%). In a consecutive autopsy series of 1700 elderly demented, the AD without joint pathologies or minor CVLs, and mixed dementia increased with age. The prevalence of “pure” VaD decreased after age >80.

One of the most common causes of these striking disparities is based on the different pathological features employed in clinical classifications.106–108

Jellinger et al pointed out various clinical, pathological, and operative definitions of VaD.10

The simplest include three significant forms: multifocal dementia, single strategic infarct dementia, and subcortical vascular encephalopathy.

Jellinger suggested a different classification of VaD, according to primary morphologic lesions, dividing it in two broad groups: multifocal/diffuse disease (which comprises: large vessel dementia; small vessel dementia, distinguishing the subcortical infarct dementia and the cortical plus subcortical infarct dementia; hypoperfusion or hypoxic-ischemic dementia; venous infarct dementia; and hemorrhagic dementia) and focal vascular disease or strategic infarct dementia.11

Because this review is focused on small vessel disease-related dementia, also called sVaD, it is essential to describe what is known about its underlying pathological mechanisms. When discussing the microcirculation, we refer to small arteries and arterioles in the pial and leptomeningeal circulation along with penetrating and parenchymal arteries and arterioles, pericytes, capillaries, and venules.

**A semantic revision of small vessel disease**

There are estimated to be approximately 47.5 million people in the world living with dementia, in up to 45% of whom SVD is a major contributing or the sole pathology.109 Markers of cerebral small vessel disease (SVD) are present on neuroimaging of almost all patients over 60. Small vessel diseases are a group of disorders that result from pathological alteration of the small blood vessels in the brain, including the small arteries, capillaries, and veins.

Cerebral small vessel disease includes neuroimaging description which comprises different imaging changes in
the white matter and subcortical grey matter, including small subcortical infarct, lacunes, white matter hyperinten-
sities (WMHs), prominent perivascular spaces (PVS), cer-
ebral microbleeds (CMBs) and atrophy. MRI studies have
questioned the enlarged perivascular spaces (PVS), also
known as Virchow-Robin spaces, as a hallmark feature of
SVD. In healthy tissue, these spaces are proposed to form
part of a complex brain fluid drainage system which sup-
ports interstitial fluid exchange and may also facilitate the
clearance of waste products from the brain. The pathophy-
siological role of PVS, their function and interaction with
cerebral microcirculation, has not been established yet. A
possible mechanism involving impaired cerebrovascular
reactivity (CVR), blood-brain barrier (BBB) dysfunction,
perivascular inflammation, leading to accumulation of tox-
ins, hypoxia and tissue damage, has been questioned.110
There is a broad consensus that PVS form a network of
spaces around cerebral microvessels acting as a canal for
fluid transport, the exchange between cerebrospinal fluid
(CSF) and interstitial fluid (ISF) and clearance of unwanted products from the brain. In human and animal
model has been proposed a brain lymphatic-like system
called “para-arteriolar,” “par-venular,” “paravascular” or
‘glymphatic. Alteration of this system may induce danger-
ous modification of brain function because undesirable
metabolic products would not be exported and nutrition
would be missed. This complex brain fluid and waste
clearance system appears to be necessary for the clearance
of interstitial solutes from the brain and is most likely vital
for maintaining brain homeostasis.111,112

Enlarged perivascular spaces (EPVS) have been related
to aging, vascular risk factors (VRF) as hypertension, and
other pathological conditions as cerebral small vessel dis-
ey and Alzheimer’s disease.

Has been reported that widening of PVS may indi-
cate obstruction by protein and cell debris and thus
stagnation of fluid drainage, those mechanisms can sup-
port PVS’s role in different diseases, for example increasing stroke risk particularly with lacunar rather
than large vessel stroke, small vessel diseases and
white matter involvement.113

The role of imaging markers of cerebral small vessel
disease is essential. Cerebral white matter hyperinten-
sities represent an essential indicator of a higher risk of all-
dementia. Moreover, covert brain infarcts and cerebral
microbleeds are potential risk indicators for incident
dementia in the general population.

The definitions and terms of these
lesions have significantly varied
among studies

As stated by Roman et al,27 the term employed to define
pathological features of the white matter as Binswanger’s
Disease is somehow misleading.

The combination of multiple small deep infarcts and
extensive white matter abnormalities has been referred to as
Binswanger disease, also known as subcortical atheroscle-
tic encephalopathy, and the clinical findings are often classi-
ified as vascular dementia of the small artery type.

White matter hyperintensities are usually symmetrically
and bilaterally distributed in the white matter including the
pons and brainstem, and also occur in deep grey matter. They
appear hyperintense to the healthy brain on T2 or FLAIR
MRI and can be confluent. The pathology of white matter
damage is still imprecise. Mainly it seems due to demyelina-
tion, loss of oligodendrocytes and axonal damage.

Other characteristics aspects are the “lacunes,” term
employed by Fisher to describe a small fluid cavity in
the brain, are very common and usually due to the
micro-infarcts and the micro-bleeds, that are mainly
located in the white matter, especially in the internal
capsule and cerebellar white matter. They can also affect
grey nuclei and deep white matter, such as the basal gang-
lia, thalamus, and brainstem white matter.

Initially, the term lacuna has been employed as a syno-
nym for lacunar strokes, for silent brain infarct and to refer
to the CSF-filled cavities on brain MRI or residual lesion
of a small hemorrhage.114–119 Nowadays, it should be
more appropriate the definition “lacuna of presumed vas-
cular origin” to replace the term “lacuna,” and it should be
avoided the term “lacunar infarct” to describe the “lacuna”
by definition. Lacunar infarcts are infarction areas, no
larger than 15 mm; less frequently, they correspond to
small hemorrhagic lesions in a reabsorption phase.120–123

Lacunes and white matter alteration share two common
findings: the same pathogenic start point, arteriosclerosis,
and brain damage vulnus, mainly a previous history of
hypertension. Lacunes, mainly due to complete occlusion
of the small arteries, lead to an infarct in a specific area
(basal ganglia, capsule, pons, etc).

Moreover, there is substantial evidence in SVD of an
associated hypoperfusive course, due to the altered caliber
of small arteries and this is associated with incomplete
ischemia of the deep white matter,124–127 accompanied
by inflammation, diffuse rarefaction of myelin sheaths, axonal disruption, and astrocyte gliosis.

In small vessel disease, occlusion of deep periventricular-draining veins is also evident, and it has been described as a disruption of the blood-brain barrier. This leads to consequent leakage of fluid and plasma cells, which eventually might potentiate the perivascular inflammation, the demyelination process, and gliosis, accomplishing a multifactorial genesis for white matter alterations.

Usually, acute small subcortical infarcts cause specific neurological symptoms, whereas cerebral small vessel disease lesions are more insidious, and referred to as silent lesions.

Finally, concerning neuroimaging findings, cerebral microbleeds, small round and homogeneous foci of hypointensity on T2-weighted (gradient echo) MRI and susceptibility-weighted imaging have been widely described. Lipofibrohyalinosis and amyloid angiopathy are the most common vascular findings with cerebral microbleeds. Distribution of CMB are different concerning the extension of the SVD pathology, CMBs can be found in the basal ganglia, thalamus, brainstem, and cerebellum; they are related to lipofibrohyalinosis, whereas amyloid angiopathy is more frequently associated with lobar CMBs. CMBs also contribute to cognitive impairment and dementia, and neurological deficits. Several studies showed a significant relationship between CMBs and Aβ accumulation. Lobar CMBs but not deep CMBs (related to SVD) was proved to be correlated with Aβ pathology.

The burden of lacunes and deep white matter alterations (WMLs) relates to the degree of cognitive impairment, mainly when they affect the thalamus and basal ganglia. The cognitive alterations are determined by the specific point-to-point impairment, but also by the interruptions of the cortico-thalamus and thalamus-cortical networks, which can also lead to cortical atrophy, secondary to functional deafferentation.

We agree with Shi and Wardlaw, who have written: common small vessel pathologies and blood-brain barrier impairment were found in clinically evident and covert cerebral small vessel disease features, suggesting that it should be regarded as a whole brain disease rather than treated separately as an individual condition.

Dynamic process for small vessel disease

Cerebral small vessel disease is a progressive disease. Lesions progress over time, and the long-term outcome and impact on brain damage vary. As far as lesions progress, cerebral small vessel disease has an uncertain long-term outcome, with a positive impact on cognition and behavior. Recent studies indicated that the strongest predictor of white matter progression is the high baseline white matter hyperintensity, with the rapid and confluent progression of lesions. Different conditions were hereafter considered.

Aging brain and vessel modifying condition

The aging of the brain is due to pathophysiological changes throughout the single lifetime.

Aging is related to vasculature changes including arteriolarosclerosis and large artery stiffening, which is much more evident in proximal elastic arteries. The arterial stiffness diminishes the so-called Windkessel effect. Windkessel is a German term, which means air chamber, but it suggests the elastic reservoir property of vessel. The walls of all the large arteries which contains muscle fibers and elastin distend during systole and recoil during diastole. Since the amount of blood entering during the systolic time is larger than the deflux of it in diastolic time, caused by peripheral resistance, the large arteries behave themselves as a capacitor. The Windkessel effects help in damping the fluctuation of blood pressure over the cardiac cycle. The Windkessel model is accompanied by the more recent theory of arterial acceleration. The onset of systole triggers a short lasting depolarization within smooth muscle cells, that spreads along the arterial tree, as a peristaltic wave; this could happen in order to amplify and distribute the pressure wave, over the arterial branches, allowing to penetrate the most profound regions.

The most determinant effect result is an anticipated and precocious return of the so-called wave reflection, an increase of systolic and the decrease of diastolic pressure. The brain usually has a high resting flow which seems to be related to the fact that heart pulsation (plus the Windkessel effect) produces a higher perfusion pressure toward the most profound small arteries of the brain.

Hypertension promotes the underlying age-related mechanism of arteriolarosclerosis, promoting micro-atheromatosis, which can rapidly lead to stenosis, or different degrees of vessel occlusion until the complete lumen occlusion, inducing ischemia and brain damage.

Besides the potential effect on arterial arteriolarosclerosis, a fundamental role is played by subsequent hemodynamic alteration that may lead to a diminishment of blood perfusion in the brain.
Like in a magic circle, the hypoperfusion, the arterio-
llosclerosis damage and the altered reflection on cerebral
blood flow velocity perpetuates the arterial stiffness.

Aging also interferes with the brain autoregulation prop-
erty. Cerebral vasoregulation is a dynamic process that redis-
tributes cerebral blood flow (CBF) toward the brain areas in
need of increased perfusion. Vasoreactivity reflects the abil-
ity of microvasculature to adapt to a changing environment,
which causes fluctuating metabolic demands (such as oxygen
and glucose delivery and blood pressure variations). As we
already reported, chronic hypertension and hypotension alter
CBF autoregulation and may affect the autoregulatory range.

“Autoregulation” most commonly refers to CBF adap-
tation to acute and chronic changes in arterial BP and
perfusion pressure. Pressure autoregulation maintains
fairly-stable perfusion over the range of mean systemic
pressures 60–150 mmHg.\textsuperscript{151–153}

Age-related endothelial dysfunction and risk factors
such as hypertension and DM set the stage for altered
neurovascular coupling and a regional decline in vasomo-
tor capacity; all those factors reshape the sigmoidal phys-
ologic curve of the adaptive system into “a straight
line.”\textsuperscript{144}

There is a strong association between hemodynamic
and structural alterations of the cerebral arteries and cog-
nitive impairment, suggesting that decreased cerebral
blood flow, diffuse brain microvascular disease, increased
arterial rigidity (resulting in decreased arterial compliance
and putative myocardial impairment) are functionally
linked to dementia. Several studies, based on transcranial
Doppler ultrasounds examination of CBF, have reported
lower mean flow velocity and decreased cerebrovascular
reactivity in the middle cerebral artery in demented
patients compared to controls.\textsuperscript{154–157}

Moreover, it has been documented marked cholinergic
denervation of small arteries in the brain.\textsuperscript{158} The lack of
muscarinic cholinergic receptors in the penetrating vessels
might lead to a vital blood flow dysregulation, with scare
response to blood pressure modifications and have as a
consequence a loss of efficacy in vasomotor coupling
response.\textsuperscript{159–161}

Finally, the aging effect involves also oxidative stress
at an early stage. The reactive oxygen species (ROS)
produced during mitochondrial oxidative phosphorylation
are associated with damage to DNA, lipids, and proteins.
The accumulation of mitochondrial DNA mutations
induces impairment of mitochondrial function. Mutations
in mitochondrial DNA and oxidative stress both contribute
to neuronal aging and neurodegeneration.\textsuperscript{162,163} All those
changes contribute to neuronal loss. The effect of aging
does not occur to the same extent in all brain regions. For
example, compared to cerebral areas, the cerebellum is
protected from aging effects. Usually, the prefrontal cortex
is most affected and the occipital least. Frontal and tem-
poral lobes are most affected in men compared with the
hippocampus and parietal lobes in women.\textsuperscript{164}

**Metabolic and regional vulnerability**

Petito et al.\textsuperscript{165} reported that after 10 mins of transient global
ischemia in the rat brain, the initial changes occur in peri-
neuronal spaces and subcortical white matter, preceding neu-
ronal death by several days.\textsuperscript{166} The authors demonstrated the
selective death of the gray matter oligodendrocytes one day
after ischemia, suggesting that oligodendroglia might be
more neurons in the cerebral cortex and thalamus, the
damage is absent or minimal. These results appear concor-
dant with other in vitro findings.\textsuperscript{167,168} Moreover, oligoden-
droglia cell death precedes neural necrosis after focal
ischemia. Furukawa et al,\textsuperscript{169} described the time course of
microglial activation after ischemia, with regional variability,
probably due to differential selectivity across brain regions,
just as what described by Gehrmann et al.\textsuperscript{170} They observed
that the most significant and precocious microglial activation
occurs in the hippocampus, soon after ischemia induction,
and this decreases after 48 h. Afterward, microglial activa-
tion is slowly evident in the white matter and cortex, with an
increasing trend, mostly at 48–72 h after ischemia induction.
Rupalla et al.\textsuperscript{171} found that in adult mice, microglial activa-
tion increased from days 2 to 30 and days 2 to 4 after
ischemia in the thalamus and cortex, respectively. Furukawa et al,\textsuperscript{169} hypothesized two subsets of microglia
activation: MI activation that induces the formation of oxi-
dative metabolites, proteases, and cytokines after ischemia,
and M2 activation that antagonizes inflammation.\textsuperscript{172} The
authors demonstrated that the extent of white matter damage
might be associated with more extensive activation of MI
microglia, implying that blocking this process could reduce
brain damage,\textsuperscript{173} following Yuan et al.\textsuperscript{167}

Chronic cerebral hypoperfusion has been proposed as
vascular risk factors for white matter injury.\textsuperscript{174} Different
experimental models which studied the hypoperfusion of
the corpus callosum with a stabilized drop of 52–64% of
the original flow at 30 days after the ligation.\textsuperscript{175} The
following white matter alteration revealed axonal damage
and diffuse demyelination, indicated by an increased amy-
lloid precursor protein expression and encephalitogenic
Oligodendrocyte degeneration was due to apoptotic cell death, with caspase 3 RNA detection, associated to an elevation of matrix-metalloprotease 2 (MMP-2) expression and microglial activation. More recent data confirmed that glial changes in chronic cerebral hypoperfusion could induce white matter damage, region-specific mild astrogliosis, marked microglial activation and increased oligodendrocyte density and diffuse myelin damage. It has been demonstrated that astrocytes react to ischemia concerning the length and severity of the insult. In the early ischemic period, the astrocytes respond with proliferation and, following persistent hypoperfusion, with degeneration and death. Interestingly, in the white matter and the frontal cortex of demented patients, the disintegration and the regression of astrocytes has been demonstrated and related to ischemia.

When the CBF is not stopped, but it is reduced or not well matched to the energy demands of the tissue, chronic brain injuries occur in different areas, standing on a different degree of vulnerability. As we documented before, the neurocentric vision of the brain is no longer supported. It is quite clear that the normal functions of the brain depend on functional interactions among different components in the neurovascular unit, which includes neurons, oligodendrocytes, microglia, and astrocytes and vascular cells (endothelial cells, pericytes, and smooth muscle cells) and the basal lamina matrix within brain vasculature. Therefore, possibly through glutamate signaling, astrocytes respond to the metabolic changes of neurons. Astrocytes monitor neuronal activity and contribute to the regulation of blood flow modifying capillary permeability, by stretching out their endfeet to the microvessel and establishing a proximal connection with the capillary. The combined effect might lead to instant regulation of CBF according to neuronal activity, in the so-called neurovascular coupling.

Moreover, endothelial cells are receiving growing interest. As pointed out by Iadecola, in the resting brain, CBF varies in proportion to the energy consumption of each brain region. Each increase in neuronal activity leads to increases in CBF in the activated areas, permitting a flow response to map brain functions. The evidence is increasing on pial arterioles: signals generated by the neuronal activity, deep in the brain, have to be conveyed to upstream arterioles, remote from the area of activation, to increase flow efficiently. Vascular mapping and fMRI demonstrated that during somatosensory activation vascular responses are first seen in the deep cortical lamina, and then, more superficially, suggesting a retrograde propagation of the vascular response. A possible scenario for the transmission and coordination of the vascular response is described by Iadecola, as follows: activation-induced increases in extracellular potassium triggers hyperpolarization of capillary endothelial cells and pericytes.

The hyperpolarization propagates upstream and reaches smooth muscle cells in penetrating arterioles producing relaxation. At the same time, metabolic modifications (reduced viscosity, increased deformability of blood cells) on the endothelium of feeding arterioles increment the smooth muscle cell relaxation (the so-called flow-mediated vasodilation). In upstream pial arterioles remote from the site of activation, there is vasodilation, by propagation from arteriole downstream and acting as a local flow-mediated and myogenic response.

Moreover, there are also regional differences in the basal regional metabolic response.

A recent in vivo study confirmed that the caudate nucleus most precociously affected brain region, followed by the putamen, insula, precentral gyrus, inferior frontal gyrus, and middle frontal gyrus, which requires, at steady state than 20% of the metabolic request, then other brain regions.

Non-demented patients with lacunar infarcts do not show cerebral flow alterations in grey matter, but they exhibit a decrease of more than 30% in white matter, associated with increased oxygen extraction of more than 130% in comparison with healthy subjects. On the contrary, patients with lacunar events and cognitive impairment have a reduced metabolic rate for oxygen, about 25% and 35% lower in grey and white matter, respectively. As a conclusion, an incongruity between the brain oxygen supply and its consumption has been described due to small vessel disease; this altered ratio causes an impaired neurovascular coupling and determines an altered vasomotor reactivity. Tak et al by employing spectroscopy confirmed a reduced blood flow and low extraction of metabolic oxygen in the frontal lobes, during the resting state in subjects with small vessel disease. These changes have been observed not only in subcortical, profound regions, but also in frontal cortical areas. This was unexpected, and not fully understood, apart from the apparent speculation that cortical damage may be related to axonal dying back or Wallerian degeneration.

Another novel aspect of the work by Tak et al is the finding that in small vessel disease, the fractional change of oxygen extraction is increased during activation tasks.
Cholinergic dysregulation in small vessel disease

A cholinergic deficit in the brain and cerebrospinal fluid of patients with vascular dementia has been widely reported. Also, cholinergic therapies have shown promising effects on cognitive improvement in those patients, even if its precise mechanisms are not well-known yet.\textsuperscript{209,210} Wilkinson et al.\textsuperscript{211} reported that patients with VAD treated with Donepezil (an acetylcholinesterase inhibitor) showed benefits in cognition and global function compared to placebo. Moreover, a significant improvement of dementia severity and slowed functional deterioration was seen.

The safety profile of donepezil has been reported in possible and probable VAD and AD; donepezil may be well tolerated, even in a relatively frail population of elderly patients with considerable comorbidities.\textsuperscript{212} Albeit, its role in VaD treatment is still debated. O’Brien and Thomas in 2015 suggested that cholinesterase inhibitors and memantine should not be used in patients with vascular dementia. Actually, in a different randomized controlled trial, a small but significant benefit of cholinesterase inhibitors on cognition was seen in vascular dementia, but the benefits on global functioning, activities of daily living, and behavior have not been consistently reported. Finally, the possible side-effects of those drugs must be taken into account.\textsuperscript{213,214}

Data suggest that the cholinergic system and cerebral blood flow are linked reciprocally. An anti-inflammatory pathway in which the efferent vagus nerve signals suppress pro-inflammatory cytokine release and inhibit inflammation has been questioned.

The concept of the “cholinergic anti-inflammation pathway” has been first proposed by Tracey et al.; these findings are based on the knowledge that acetylcholine (Ach) released from cholinergic axon terminals can interact with α7 nicotinic Ach receptors (nAChRs) on visceral immune cells.\textsuperscript{215,216} The nicotinic receptors then translate the cholinergic signal into the suppression of cytokine release, involved in the inflammatory cascade.\textsuperscript{217,218}

Cholinergic agents include Ach precursors, which increase the synthesis of Ach; nicotinic or M1 muscarinic agonists, which directly stimulate cholinergic receptors or allosterically modulate AChR,\textsuperscript{219} and synaptic AChE inhibitors, which prevent the degradation of Ach.

Data from literature showed that both in animal models and postmortem studies there is reduced CSF Ach concentrations in patients withBinswanger or multi-infarct dementia.\textsuperscript{220,221} Animal models of sVaD (stroke-prone rats) show significant reductions in ACh levels in the cortex, hippocampus, and cerebrospinal fluid.\textsuperscript{222-225} Furu kawa et al.\textsuperscript{226} investigated the role of ACh in the development of hypoxia-ischemia lesions using in vivo animal models. They demonstrated that muscarinic receptor antagonism with atropine has a selective effect of worsening the ischemic damage, but only in the CA1 region. Selective alpha-7- nicotinic AChR antagonists exacerbate changes in the cortex and CA1 and CA3 areas, while non-selective nicotinic AChR antagonists have a detrimental effect on the hippocampus but not in all the cortical areas examined.\textsuperscript{227} It is accepted that AChR stimulation reduces hypoxic-ischemic brain damage in rat pups and reduces the cytokine production as a consequence of hypoxia-ischemia damage.\textsuperscript{228-230} Elsewhere a loss of cholinergic neurons in 40% of VaD patients was reported, accompanied by reduced ACh activity in the cortex, hippocampus, and striatum.\textsuperscript{231}

Changes in cerebral blood flow can affect control cholinergic networks, and a proper cholinergic function is mandatory to regulate regional brain blood flow.\textsuperscript{232,233} In primates, the central cholinergic system has three main components: the projections from the basal forebrain, innervating the hippocampus, cortical regions, and some subcortical nuclei; the projections from the brainstem which innervate the thalamus and the midbrain, as well as the brainstem; finally, the striatal and accumbens interneurons.\textsuperscript{234,235}

The forebrain cholinergic bundle is supplying both the medial and lateral pathways loops around the anterior corpus callosum and the frontal horns of the ventricles. It is well-accepted the parasympathetic innervation of the circle
of Willis, and pial vessels are principally mediated by Ach.\textsuperscript{236} Ach produces significant in vitro arterial relaxation per se and by increasing the synthesis of vasodilator endothelium agents, via the nitric oxide synthase,\textsuperscript{237} and via the GABA interneurons.\textsuperscript{238–240}

The stimulation of the Nucleus Basalis of Meynert results in increased blood flow throughout the cerebral cortex in experimental animals.\textsuperscript{241} On stimulation, perivascular cortical afferents release Ach into endothelial M5 muscarinic receptor.\textsuperscript{242,243} M5 receptors are highly expressed in blood vessel walls. Yamada et al.\textsuperscript{222} prepared knockout mice (M5-/-) and found that compared to wild-type mice, these animals lose the ability to dilate cerebral arteries but could still regulate extra-cerebral flow; it has been suggested that the neural network from the Meynert nucleus may influence the small arteries also indirectly.

Age-related impairment of vascular autoregulation is also due to a low-level functioning of the autonomic nervous system, with direct and endothelium-mediated altered baroreflex activity.\textsuperscript{244–246}

Small vessel disease, due to the primary localization of the white matter hyperintensities, may affect the integrity of the adjacent medial cholinergic pathway.\textsuperscript{247} Post-mortem studies in CADASIL demonstrated that cortical cholinergic projections from the Meynert could be affected as a consequence of white matter lesions. Bohnen et al.\textsuperscript{247} demonstrated in vivo that the severity of the periventricular white matter lesions is associated with lower AchE activity, in the middle-aged and elderly subjects without dementia, as a result of cortical cholinergic deafferentation.

Post-mortem sVaD studies revealed lower choline acetyltransferase (ChAT) activity compared with controls,\textsuperscript{248} and sVaD patients have lower CSF concentrations of Ach.\textsuperscript{223–225,249}

There are some clinical data which confirm a reduction of the number of cholinergic neurons in the Nucleus Basalis of Meynert in multi-infarct dementia, but not in sVaD.\textsuperscript{250–252} Though, the number of muscarinic cholinergic receptors is markedly reduced in mixed dementia patients,\textsuperscript{253} and in small vessel disease-related dementia. The cholinergic impairment is not mediated by a primary loss of the cholinergic neurons of Nucleus Basalis of Meynert,\textsuperscript{254,255} but rather it is a consequence of the secondary cholinergic deficits, due to the indirect less efficacious endothelium mediation through the nitric oxide synthase and the GABA interneurons.\textsuperscript{237,238} The two mediators seem less efficient to influence the small arteries contraction also due to the significant coexistent alterations of the endothelium.\textsuperscript{256–259}

The pathological cascade of events, which occurs as a consequence of all the pathological alterations described, determines a decrease of the vascular tone, with a release of the blood-brain barrier permeability, with internal vascular remodeling and with vascular rarefactions. As a result, hypo-perfusion at rest occurs in the brain, combined with an impairment in the moment-to-moment control of CBF, associated to a decrease of adaptive vascular responses and a diminishment of the neurovascular coupling and auto-regulation system.\textsuperscript{257}

More recent studies have suggested an important role for the autonomic nervous system in the maintenance of cerebral perfusion.\textsuperscript{260–262} It has been suggested that cholinesterase inhibitors modulate cerebral vascular functions, due to the possible role of the cholinergic fibers in cerebral flow regulation.\textsuperscript{263} Moreover, an active cholinergic vasodilatory reflex in the cerebrovascular system has significant clinical implications for the use of acetylcholinesterase inhibitors in the potential adjuvant treatment for ischemic strokes.\textsuperscript{264} Moreover, the same authors demonstrated that increasing cholinergic activity might also improve cerebral perfusion and autoregulation in demented patients.\textsuperscript{265} Once more, the distribution of muscarinic receptor subtypes may play a key role in how vasodilation is affected: in skeletal muscle, M3 receptors are dominant and are responsible for the vasodilatory response to acetylcholine.\textsuperscript{266} On stimulation, perivascular cortical afferents release Ach onto endothelial M5 muscarinic receptor,\textsuperscript{267,268} highly expressed in blood vessel walls.\textsuperscript{267} Hamner et al.\textsuperscript{261} in a limited, but well-conducted study demonstrated in healthy volunteers that cholinergic control of the cerebral vasculature might be active at low frequencies, lower than 0.05 Hz when the sympathetic nervous system appears to play a role in the cerebral auto-regulation. At these low frequencies, even the myogenic mechanisms appear to play any role; to surprise, the correspondence between cholinergic and sympathetic cerebrovascular regulation above 0.05 Hz is striking, suggesting that the cerebral circulation engages different mechanisms to protect against rising and falling pressures.

It has been demonstrated that the endothelial cells of brain arterioles promote and activates the neuronal signaling, the synaptic transmission, oligodendrocyte and white matter regulation, neurogenesis while inhibiting the activation of the microglia.\textsuperscript{269,270}

Moreover, the cholinergic impairment for artery dysregulation observed in small vessel disease could also derive from
the deafferentation of the basal forebrain cholinergic system to the subcortical structures. These findings are associated with a reduced synaptophysin immunoreactivity. In animal models, a reduction of vasopressin and histamine has been confirmed as a result of the deafferentation of the neural tracts from the supra-optic and tuberomammillary nuclei to the basal forebrain, with a possible self-potentiating reduction of perfusion.

The presence of lacunes and white matter lesions affecting the deep neural networks located between frontal cortical areas and basal ganglia/thalamus and anterior cingulate cortex, may account for secondary cholinergic basal-forebrain de-afferentation. Neural activity is typically accompanied by increased blood flow, with vascular dilatation propagated in a retrograde manner to upstream arterioles, located outside the activated area. The altered “retrograde vasodilatation system” (which occurs in small vessel disease-related dementia) could be a possible factor that may worsen vessel dysregulation.

**Small vessel disease: yin and yang in subcortical vascular dementia**

Small vessel disease and white matter abnormalities are seen frequently with aging.

The most relevant questions are: does the coexistence of small vessel disease and white matter alterations do represent a biological variant of healthy aging, or is small vessel disease the predictor of future dementia?

The answers are ambiguous.

Animal models and human clinical studies showed that white matter alterations are associated with cognitive and behavioral disruptions. Though, as clearly stated by De Silva and Faraci, “the associations between vascular disease and cognition are based primarily on the temporal relationship between these endpoints.”

What is lacking is a solid demonstration of the existence of a causative determinant, testifying the relation between subcortical networks disruption (due to small vessel disease) and the clinical definition of subcortical vascular dementia.

What emerges from literature are some statements: first of all, vascular and endothelium changes have been related with age; the changes can be accelerated by different vascular risk factors (hypertension, hemodynamic changes, diabetes); secondly, vascular function changes can be heavily influenced by genetic and epigenetic factors; they directly influence the endothelium resistance. These changes induce a progressive decrease in CBF which is thought to be one of the key elements for the progression from small vessel disease towards subcortical vascular dementia. Aging is the most important non-modifiable risk factor for the development of white matter hyperintensities and their progression towards confluent white matter damage, for endothelium injuries, for their progression and the increased blood-brain barrier permeability. Moreover, the subcortical vascular dementia might be characterized by focal, even subtle neurological signs (such as slight motor hemiparesis, bulbar signs, gait imbalance, hypokinesia, etc.).

Another important key point is that the early cognitive syndrome for subcortical vascular dementia is defined by a dis-executive syndrome, with decreased abilities in goal formulation, set-shifting, and execution, associated to major problems in the retrieval of information. Similarly, behavior disruption is even more typical, with marked emotional lability, emotional bluntness, and apathy. What has been described as a typical neuropsychological profile of subcortical vascular dementia can be attributed to damage to the prefrontal-frontal subcortical cortical networks.

Tak et al. found significant alterations of the hemodynamic and metabolic responses also in the frontal cortical areas of patients suffering from small vessel disease. This can be related to axonal dying back or Wallerian degeneration, but it is also supported by a metabolic imbalance, due to an increased fractional change of oxygen extraction, during activation tasks, not sufficient to compensate for the constant decrease of CBF and the low metabolic oxygen rate. The increased oxygen extraction implies a progressive loss of the metabolic reserve.

Different studies pointed out that even in the healthy aging brain, some cognitive, age-related modalities have been related to frontal lower metabolism. The ongoing process or sudden precipitating events may transform the standard aging-related subcortical alteration in dementia.

The cerebral small vessel disease has been traditionally distinguished from a neuropsychological perspective from subcortical vascular dementia. A well-conducted study stated that lacunar infarctions and deep white matter hyperintensities seen on MRI did not correlate with neuropsychological impairments and they should be considered as “epiphenomena that morphologically characterize cerebral small vessel disease, but do not, in and themselves, indicate cognitive impairment.” Nonetheless, different studies indicated that lacunes and white matter hyperintensities were
associated with dis-executive syndrome,^296,297^ and when lacunar events can be thoroughly studied, neuropsychological dis-executive functions can be found out in more than 55% of cases, concluding that the process from small vessel disease to subcortical vascular dementia is ongoing and its incidence is still under-recognized, in clinical and research studies.^298^ These conclusions are in line with those derived by more consistent studies and even recent studies.^299,300^ These studies indicated that most of their participants, affected by small vessel disease, demonstrated cognitive performances, below one standard deviation from the normative mean scores in executive functions. These data suggest therefore that small vessel disease could be considered as a fore-runner condition of subcortical dementia, in due time course.

Finally, the pattern progression from small vessel disease to subcortical dementia has been debated by two more recent works. Nitkunan et al.^301^ verified that the cognitive and executive dys-functions are related to the brain volume decline, which is progressive with time course. More sophisticated studies,^302,303^ suggested that the progression pattern of brain structural changes in patients with small vessel disease is consistent with the topography of selective cortical atrophy (mainly in frontal, perisylvian and posterior cingulate regions).^304–307^ The atrophy extends further towards the parietal and medial temporal regons, when patients manifested the definite signs of subcortical vascular dementia, exhibiting additional atrophy in the lateral head and inferior body of the hippocampus.

Taken together, all the data as mentioned earlier indicate that patients with small vessel disease manifest cognitive and behavioral impairments. They are consistent with subcortical frontal networks disruption and their evolution towards subcortical vascular dementia is consistent with the progression of the cortical thinning of prefrontal, frontal areas and with an evident shape alteration of the lateral head and inferior body of the hippocampus. Still debated aspects are time course, precipitating factors, and individual variability.^308^

**Conclusions**

At the end of this review, there are some solid conclusions and many points that require further studies. The positive aspects are:

1. Small vessel disease and the related dementia are two unambiguous nosographic entities that deserve attention for their relevance and impact in clinical practice.
2. Hypertension might be a historical problem of patients who suffer from small vessel disease and small vessel disease-related dementia, but at the diagnosis of small vessel disease, patients are more vulnerable to brisk pressure lowering
3. CBF regional selective decrease seems to be one of the critical factors for the progression from small vessel disease to small vessel disease-related dementia.
4. The arterioles are the targets of small vessel disease and sVaD, with degeneration of the smooth muscle layer, replacement by hyaline fibrosis, leading to a subtotal luminal occlusion. Patients suffering from small vessel pathology are therefore more sensitive to any pressure changes. Endothelium damage is a super-imposed, not irrelevant, condition.^309^
5. Acetylcholine intimately regulates CBF through the parasympathetic innervation of the circle of Willis and pial vessels. It causes significant arterial relaxation by promoting the synthesis of vasodilator agents; a secondary acetyl-cholinergic impaired regulation characterizes small vessel disease.
6. These aspects determine the sensitivity of elderly patients with dementia to hypotension and each clinical condition that may lead to hypotension might accelerate underlying degenerative processes.

The most relevant still under debate-aspects are:

1. The modality of changing from normal aging small vessel disease towards dementia
2. The influence of cells, other than neurons and astrocytes, including microglia, oligodendrocytes, perivascular and meningeal macrophages in vessel control and endothelium degeneration
3. The impact of aging and the age-gene interactions in lipohyalinosis and endothelium disruption, caused, promoted or potentiated by hypoperfusion and metabolic disruption.

**Acknowledgments**

The authors thank Joy Bates, PhD for her assistance in editing the text and express their gratitude to Claudio Tiribelli, MD PhD, full professor, for his revision of the text, in order to implement its clarity and its rigor.
Disclosure
The authors declare that they have no actual or potential conflicts of interest in relation to this article.

References


119. Jouvet A, Faraci FM. Cerebral small vessel disease: insights and opportunities from mouse models of collagen IV related small vessel disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. *Stroke* 2014;45:1215–1221. doi:10.1161/STROKEAHA.113.002878


